AbbVie has completed the acquisition of Pharmacyclics, Inc., expanding its oncology assets in a transaction valued at $21 billion. Pharmacyclics markets Imbruvica (ibrutinib), a BTK-inhibitor used to treat hematological cancers, which represents a $24 billion global market.   Imbruvica is approved for use in four indications in the U.S. and received three Breakthrough Therapy designations by the FDA. AbbVie plans to explore its five late-stage assets in combination with Imbruvica to evaluate the...